Elotuzumab
AbbVie,BMS
['mmsm', 'carfilzomib']
#asco23 #mmsm notice the following: carfilzomib dosing: d1/2, 8/9 and 15/16 (20 mg/m iv on d 1/2 in c1 and 36 mg/m thereafter) why they choose the primary endpoint 
Assistant professor @UAMSMyeloma. Alumni heme/onc @bcmhouston, clinical research/biostat @UMich.Focus on plasma cell disorders & health disparities